BiotechTube

Amevive (Alefacept) + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lichen Planus

Conditions

Lichen Planus

Trial Timeline

Apr 1, 2004 → Dec 1, 2004

NCT ID
NCT00135733

About Amevive (Alefacept) + Placebo

Amevive (Alefacept) + Placebo is a phase 2 stage product being developed by Biogen for Lichen Planus. The current trial status is terminated. This product is registered under clinical trial identifier NCT00135733. Target conditions include Lichen Planus.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00135733Phase 2Terminated

Competing Products

12 competing products in Lichen Planus

See all competitors
ProductCompanyStageHype Score
LP-10 (Liposomal Tacrolimus)Lipella PharmaceuticalsPhase 2
44
Tacrolimus cream + Clobetasol creamAstellas PharmaPhase 2
52
Baricitinib 4 milligram Oral TabletEli LillyPhase 2
52
pimecrolimus and clobetasol + clobetasol 0.05% creamNovartisPhase 2
52
Pimecrolimus 1% creamNovartisPhase 2
52
secukinumab 300 mg Q4W + secukinumab 300 mg Q2WNovartisPhase 2
52
Apremilast + PlaceboAmgenPhase 2
51
DeucravacitinibBristol Myers SquibbPhase 2
51
Dupilumab + PlaceboSanofiPhase 3
76
Dupilumab + PlaceboSanofiPhase 3
76
Ruxolitinib cream + Vehicle creamIncytePhase 2
49
Ruxolitinib cream + Vehicle creamIncytePhase 2
49

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved
82
Dimethyl fumarateApproved
82
[18F]Florbetapir PET imagingApproved
82
dimethyl fumarateApproved
82
ibritumomab tiuxetan (Zevalin®)Approved
82